Constitutively Active Death Receptor (CADRE) ID: 2025-001

A novel anticancer therapeutic designed to induce apoptosis specifically in cancer cells by utilizing a modified, always active death receptor.

Technology Overview

CADRE represents a groundbreaking approach in cancer treatment, leveraging a modified death receptor that triggers apoptosis directly within cancer cells, bypassing their typical resistance to cell death. This technology aims to selectively target and destroy cancer cells without harming normal cells, offering a more effective and less toxic alternative to traditional cancer therapies.

Key Advantages

• High specificity to cancer cells, minimizing damage to normal cells
• Overcomes resistance mechanisms often presented by cancer cells against conventional therapies
• Potential to be more broadly applicable than current targeted therapies like CAR T-cell therapy
• Customizable for different cancer types through specific delivery mechanisms

Problems Addressed

• Non-specificity of traditional cancer treatments such as chemotherapy and radiotherapy, which also damage healthy cells
• Resistance of cancer cells to current therapies, leading to treatment failure
• Limited applicability of advanced therapies like CAR T-cell therapy to a wide range of cancers

Additional Information

Technology ID: 2025-001
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 21 April, 2025